Seres Therapeutics (MCRB) Income towards Parent Company (2016 - 2026)
Seres Therapeutics (MCRB) has disclosed Income towards Parent Company for 10 consecutive years, with $139.8 million as the latest value for Q3 2024.
- Quarterly Income towards Parent Company rose 2144.32% to $139.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $139.8 million through Jun 2025, up 612.62% year-over-year, with the annual reading at $125.9 million for FY2024, 64.79% up from the prior year.
- Income towards Parent Company hit $139.8 million in Q3 2024 for Seres Therapeutics, up from -$6.7 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $139.8 million in Q3 2024 to a low of -$71.5 million in Q1 2023.
- Historically, Income towards Parent Company has averaged -$13.1 million across 5 years, with a median of -$20.2 million in 2020.
- Biggest five-year swings in Income towards Parent Company: tumbled 197.27% in 2023 and later skyrocketed 2144.32% in 2024.
- Year by year, Income towards Parent Company stood at -$18.0 million in 2020, then crashed by 175.35% to -$49.7 million in 2021, then soared by 95.58% to -$2.2 million in 2022, then crashed by 197.27% to -$6.5 million in 2023, then skyrocketed by 2240.73% to $139.8 million in 2024.
- Business Quant data shows Income towards Parent Company for MCRB at $139.8 million in Q3 2024, -$6.7 million in Q2 2024, and -$7.2 million in Q1 2024.